Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer

被引:20
|
作者
Tanner, Edward J. [1 ]
Long, Kara C. [1 ]
Zhou, Qin [2 ]
Brightwell, Rachel M. [1 ]
Gardner, Ginger J. [1 ]
Abu-Rustum, Nadeem R. [1 ]
Leitao, Mario M., Jr. [1 ]
Sonoda, Yukio [1 ]
Barakat, Richard R. [1 ]
Iasonos, Alexia [2 ]
Chi, Dennis S. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10065 USA
关键词
Cytoreductive surgery; Advanced ovarian cancer; Operative start time; QUALITY-IMPROVEMENT; SLEEP-DEPRIVATION; SURGERY; SURVIVAL; MORBIDITY; PERFORMANCE; CARCINOMA; DISEASE; PART;
D O I
10.1016/j.ygyno.2012.04.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. To evaluate the impact of operative start time (OST) on surgical outcomes in patients with advanced ovarian cancer. Methods. All stage IIIB-IV serous ovarian cancer patients who underwent primary surgery at our institution from 1/01 to 1/10 were identified. Fourteen factors were evaluated for an association with surgical outcomes including OST and OR tumor index (1 point each for carcinomatosis and/or bulky [>= 1 cm] upper abdominal disease). Univariate logistic regression considering within-surgeon clustering was performed for cytoreduction to <= 1 cm versus > 1 cm residual disease. In patients with <= 1 cm residual disease, univariate logistic regression considering within-surgeon clustering was performed for 1-10 mm residual disease versus complete gross resection (CGR, 0 mm residual). A multivariate logistic model was developed based on univariate analysis results in the <= 1 cm residual disease cohort. Results. Of 422 patients, residual disease was: 0 mm, 144 (34.1%); 1-10 mm, 175 (41.5%); > 10 mm, 103 (23.3%). OST was not associated with cytoreduction to <= 1 cm residual disease on univariate analysis. In the <= 1 cm residual disease cohort, albumin, CA-125, ascites, ASA score, stage, OR tumor index, and OST were associated with CGR on univariate analysis. Earlier OSTs were associated with increased rates of CGR. On multivariate analysis, CA-125 was independently associated with CGR. OST was associated with CGR in patients with an OR tumor index of 2 but not an OR tumor index < 2. Conclusions. OST was not associated with cytoreduction to <= 1 cm residual disease in patients with advanced serous ovarian cancer. In the cohort of patients with <= 1 cm residual disease, later OSTs were associated with reduced rates of CGR in patients with greater tumor burden. (c) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:58 / 63
页数:6
相关论文
共 50 条
  • [1] Does operative start time impact the frequency of complete gross resection in patients undergoing primary cytoreduction for advanced serous ovarian carcinoma?
    Tanner, E.
    Long, K.
    Zhou, Q.
    Brightwell, R.
    Gardner, G.
    Abu-Rustum, N.
    Leitao, M.
    Sonoda, Y.
    Barakat, R.
    Iasonos, A.
    Chi, D.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : S2 - S2
  • [2] Primary cytoreduction in advanced ovarian cancer: 'Biologic and surgical aggressiveness'
    Aletti, Giovanni D.
    Cliby, William A.
    ONCOLOGY-NEW YORK, 2008, 22 (09): : 1041 - +
  • [3] Does intraoperative hypothermia contribute to postoperative morbidity in patients undergoing optimal primary surgical cytoreduction for advanced ovarian cancer?
    Long, K.
    Tanner, E.
    Frey, M.
    Cormier, B.
    Gardner, G.
    Sonoda, Y.
    Levine, D.
    Brown, C.
    Barakat, R.
    Chi, D.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S104 - S104
  • [4] Critique of surgical cytoreduction in advanced ovarian cancer
    Covens, AL
    GYNECOLOGIC ONCOLOGY, 2000, 78 (03) : 269 - 274
  • [5] Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes
    Peiretti, Michele
    Bristow, Robert E.
    Zapardiel, Ignacio
    Gerardi, Melissa
    Zanagnolo, Vanna
    Biffi, Roberto
    Landoni, Fabio
    Bocciolone, Luca
    Aletti, Giovanni Damiano
    Maggioni, Angelo
    GYNECOLOGIC ONCOLOGY, 2012, 126 (02) : 220 - 223
  • [6] Laparoscopic Cytoreduction for Primary Advanced Ovarian Cancer
    Fanning, James
    Hojat, Rod
    Johnson, Jil
    Fenton, Bradford
    JSLS-JOURNAL OF THE SOCIETY OF LAPAROENDOSCOPIC SURGEONS, 2010, 14 (01) : 80 - 82
  • [7] A proteomic analysis of surgical cytoreduction in patients with advanced ovarian cancer.
    Lesnock, Jamie L.
    Hood, Brian L.
    Sun, Mai
    Bhargava, Rohit
    Conrads, Thomas P.
    Krivak, Thomas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Weekly induction intraperitoneal chemotherapy after primary surgical cytoreduction in patients with advanced epithelial ovarian cancer
    Zang R.Y.
    Li Z.T.
    Tang J.
    Huang X.
    Cai S.M.
    World Journal of Surgical Oncology, 4 (1)
  • [9] THE IMPACT OF ERAS IN CYTOREDUCTION FOR ADVANCED OVARIAN CANCER
    Tsolakidis, D.
    Zouzoulas, D.
    Markopoulou, E.
    Chatzistamatiou, K.
    Zymperdikas, C.
    Anthoulakis, C.
    Mikos, T.
    Zepeiridis, L.
    Mpili, E.
    Pados, G.
    Papanikolaou, A.
    Grimbizis, G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A241 - A241
  • [10] Role of aggressive surgical cytoreduction in advanced ovarian cancer
    Chang, Suk-Joon
    Bristow, Robert E.
    Chi, Dennis S.
    Cliby, William A.
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2015, 26 (04) : 336 - 342